Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 7/20 | 0.40 |
| ▸ | IL23R | Q5VWK5 | 5/20 | 0.39 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
| ▸ | MAGI3 | Q5TCQ9 | 1/20 | 0.36 |
| ▸ | CTSD | P07339 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30632039 | 0.97 | IL23R (0.40) | BACE1IL23RMAGI3 | |
| SCHEMBL21766761 | 0.90 | BACE1 (0.41) | BACE1BACE2PTPN1MAGI3 | |
| SCHEMBL30632040 | 0.89 | FURIN (0.40) | BACE1 | |
| SCHEMBL30632045 | 0.88 | MAGI3 (0.39) | BACE1IL23RBACE2PTPN1MAGI3 | |
| SCHEMBL29904276 | 0.84 | BACE1 (0.41) | BACE1BACE2CTSD | |
| SCHEMBL21766714 | 0.84 | BACE1 (0.38) | BACE1BACE2CTSD | |
| SCHEMBL20397511 | 0.84 | KDM4E (0.43) | — | |
| SCHEMBL20397515 | 0.84 | KDM4E (0.43) | — | |
| SCHEMBL31746072 | 0.83 | PTPN1 (0.49) | BACE1BACE2PTPN1 | |
| SCHEMBL21766788 | 0.83 | SIRT2 (0.41) | BACE1IL23RBACE2PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11771774-B2 | Nerve labeling compositions and uses thereof | AVELAS ACQUISITION CORPORATION (US) | 2023-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11771774-B2 | Nerve labeling compositions and uses thereof | GAP43, NGF, PMP22 | BACE1 787/4885IL23R 4181/4885BACE2 728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.